Spectrum of <em>PAH</em> gene variants in Jordanian patients with phenylalanine hydroxylase deficiency

Fathallah,Rajaa; Al‑Rashed,Khadeeja; Arafat,Alaa; Awwad,Hanan; Maraqa,Latifa; El‑Khateeb,Mohammed; Shboul,Mohammad

doi:10.3892/br.2025.2029

Spectrum of PAH gene variants in Jordanian patients with phenylalanine hydroxylase deficiency

Authors:
- Rajaa Fathallah
- Khadeeja Al‑Rashed
- Alaa Arafat
- Hanan Awwad
- Latifa Maraqa
- Mohammed El‑Khateeb
- Mohammad Shboul
View Affiliations

Affiliations: National Center for Diabetes, Endocrinology and Genetics, Amman 11942, Jordan, PKU and Genetic Consultation Clinic, Ministry of Health, Amman 86, Jordan, Department of Medical Laboratory Sciences, Faculty of Medical Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan
Published online on: July 3, 2025 https://doi.org/10.3892/br.2025.2029
Article Number: 151
Copyright: © Fathallah et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene. PKU is considered as one of the most common autosomal recessive diseases in Jordan; however, the spectrum of gene variants is yet to be determined. The present study aimed to identify the PAH genetic variants in a cohort of Jordanian children diagnosed with PKU. A total of 77 affected patients from 50 families were enrolled in the present study. All exons as well as exon‑intron boundaries of the PAH gene were analyzed by Sanger sequencing. Segregation analysis was performed on the available family members. A total of 23 distinct PAH variants were identified with a detection rate of 100%. All variants were either pathogenic or likely pathogenic. These variants included 9 missense (39.1%), 6 splice site (26.1%), 4 frameshift (17.4%), 2 nonsense (8.7%) and 2 in‑frame deletion (8.7%) variants. Among these variants, one was novel [c.781del; p.(Arg261Glufs80)]. The present study highlighted the wide spectrum of disease‑causing variants in the PAH gene among Jordanian patients. The findings also underscore the importance of establishing region‑specific genetic screening. Early genetic diagnosis of PKU will facilitate timely treatment and management of affected patients, risk stratification and genetic counseling, thereby reducing the burden of PKU in Jordan.

View Figures

View References

1	van Wegberg AMJ, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Giżewska M, et al: The complete European guidelines on phenylketonuria: Diagnosis and treatment. Orphanet J Rare Dis. 12(162)2017.PubMed/NCBI View Article : Google Scholar
2	Vieira Neto E, Laranjeira F, Quelhas D, Ribeiro I, Seabra A, Mineiro N, D M Carvalho L, Lacerda L and G Ribeiro M: Mutation analysis of the PAH gene in phenylketonuria patients from Rio de Janeiro, Southeast Brazil. Mol Genet Genomic Med. 6:575–591. 2018.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print).
3	van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N and Bosch AM: Phenylketonuria. Nat Rev Dis Primers. 7(36)2021.PubMed/NCBI View Article : Google Scholar
4	Dababneh S, Alsbou M, Taani N, Sharkas G, Ismael R, Maraqa L, Nemri O, Al-Jawaldeh H, Kopti N, Atieh E and Almasri A: Epidemiology of phenylketonuria disease in Jordan: Medical and nutritional challenges. Children (Basel). 9(402)2022.PubMed/NCBI View Article : Google Scholar
5	Blau N, van Spronsen FJ and Levy HL: Phenylketonuria. Lancet. 376:1417–1427. 2010.PubMed/NCBI View Article : Google Scholar
6	Schuck PF, Malgarin F, Cararo JH, Cardoso F, Streck EL and Ferreira GC: Phenylketonuria pathophysiology: On the role of metabolic alterations. Aging Dis. 6:390–399. 2015.PubMed/NCBI View Article : Google Scholar
7	van Spronsen FJ, van Wegberg AM, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Giżewska M, et al: Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 5:743–756. 2017.PubMed/NCBI View Article : Google Scholar
8	Elhawary NA, AlJahdali IA, Abumansour IS, Elhawary EN, Gaboon N, Dandini M, Madkhali A, Alosaimi W, Alzahrani A, Aljohani F, et al: Genetic etiology and clinical challenges of phenylketonuria. Hum Genomics. 16(22)2022.PubMed/NCBI View Article : Google Scholar
9	Woo SLC, Lidsky AS, Güttler F, Chandra T and Robson KJH: Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of classical phenylketonuria. Nature. 306:151–155. 1983.PubMed/NCBI View Article : Google Scholar
10	Hillert A, Anikster Y, Belanger-Quintana A, Burlina A, Burton BK, Carducci C, Chiesa AE, Christodoulou J, Đorđević M, Desviat LR, et al: The genetic landscape and epidemiology of phenylketonuria. Am J Hum Genet. 107:234–250. 2020.PubMed/NCBI View Article : Google Scholar
11	Scriver CR, Hurtubise M, Konecki D, Phommarinh M, Prevost L, Erlandsen H, Stevens R, Waters PJ, Ryan S, McDonald D and Sarkissian C: PAHdb 2003: What a locus-specific knowledgebase can do. Hum Mutat. 21:333–344. 2003.PubMed/NCBI View Article : Google Scholar
12	Sambrook J and Russell DW: Molecular Cloning: A Laboratory Manual. Vol 1. 3rd edition. Cold Spring Harbor Laboratory Press, New York, ΝΥ, 2001.
13	Zastrow DB, Baudet H, Shen W, Thomas A, Si Y, Weaver MA, Lager AM, Liu J, Mangels R, Dwight SS, et al: Unique aspects of sequence variant interpretation for inborn errors of metabolism (IEM): The ClinGen IEM working group and the phenylalanine hydroxylase gene. Hum Mutat. 39:1569–1580. 2018.PubMed/NCBI View Article : Google Scholar
14	Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M, et al: Sherloc: A comprehensive refinement of the ACMG-AMP variant classification criteria. Genet Med. 19:1105–1117. 2017.PubMed/NCBI View Article : Google Scholar
15	Ajami N, Soleimani A, Jafarzadeh-Esfehani R, Hasanpour M, Rashid Shomali R and Abbaszadegan MR: Mutational landscape of phenylketonuria in Iran. J Cell Mol Med. 27:2457–2466. 2023.PubMed/NCBI View Article : Google Scholar
16	Jeannesson-Thivisol E, Feillet F, Chéry C, Perrin P, Battaglia-Hsu SF, Herbeth B, Cano A, Barth M, Fouilhoux A, Mention K, et al: Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness. Orphanet J Rare Dis. 10(158)2015.PubMed/NCBI View Article : Google Scholar
17	Kleiman S, Bernstein J, Schwartz G, Eisensmith RC, Woo SL and Shiloh Y: A defective splice site at the phenylalanine hydroxylase gene in phenylketonuria and benign hyperphenylalaninemia among Palestinian Arabs. Hum Mutat. 1:340–343. 1992.PubMed/NCBI View Article : Google Scholar
18	Carducci C, Amayreh W, Ababneh H, Mahasneh A, Al Rababah B, Al Qaqa K, Al Aqeel M, Artiola C, Tolve M, D'Amici S, et al: Molecular genetics of phenylketonuria and tetrahydrobiopterin deficiency in Jordan. JIMD Rep. 55:59–67. 2020.PubMed/NCBI View Article : Google Scholar
19	Aldámiz-Echevarría L, Llarena M, Bueno MA, Dalmau J, Vitoria I, Fernández-Marmiesse A, Andrade F, Blasco J, Alcalde C, Gil D, et al: Molecular epidemiology, genotype-phenotype correlation and BH4 responsiveness in Spanish patients with phenylketonuria. J Hum Genet. 61:731–744. 2016.PubMed/NCBI View Article : Google Scholar
20	Wang R, Shen N, Ye J, Han L, Qiu W, Zhang H, Liang L, Sun Y, Fan Y, Wang L, et al: Mutation spectrum of hyperphenylalaninemia candidate genes and the genotype-phenotype correlation in the Chinese population. Clin Chim Acta. 481:132–138. 2018.PubMed/NCBI View Article : Google Scholar
21	Zhu T, Ye J, Han L, Qiu W, Zhang H, Liang L and Gu X: Variations in genotype-phenotype correlations in phenylalanine hydroxylase deficiency in Chinese Han population. Gene. 529:80–87. 2013.PubMed/NCBI View Article : Google Scholar
22	Yan Y, Zhang C, Jin X, Zhang Q, Zheng L, Feng X, Hao S, Gao H and Ma X: Mutation spectrum of PAH gene in phenylketonuria patients in Northwest China: Identification of twenty novel variants. Metab Brain Dis. 34:733–745. 2019.PubMed/NCBI View Article : Google Scholar
23	Esfahani MS and Vallian S: A comprehensive study of phenylalanine hydroxylase gene mutations in the Iranian phenylketonuria patients. Eur J Med Genet. 62(103559)2019.PubMed/NCBI View Article : Google Scholar
24	Al-Faris MZ and Takruri HR: Study on the prevalence of phenylketonuria in Jordan and assessment of follow-up efforts and dietary management of patients with this disease. Med J Nutrition Metab. 7:95–106. 2014.
25	Al-Qa K, Amayreh W and Al-Hawamdeh A: Spectrum of inborn errors of metabolism in Jordan: Five years experience at King Hussein medical center. J R Med Serv. 19:37–41. 2012.
26	Gundorova P, Stepanova AA, Kuznetsova IA, Kutsev SI and Polyakov AV: Genotypes of 2579 patients with phenylketonuria reveal a high rate of BH4 non-responders in Russia. PLoS One. 14(e0211048)2019.PubMed/NCBI View Article : Google Scholar
27	Guldberg P, Henriksen KF, Sipilä I, Güttler F and De La Chapelle A: Phenylketonuria in a low incidence population: Molecular characterisation of mutations in Finland. J Med Genet. 32:976–978. 1995.PubMed/NCBI View Article : Google Scholar
28	Muntau AC, Adams DJ, Bélanger-Quintana A, Bushueva TV, Cerone R, Chien YH, Chiesa A, Coşkun T, de Las Heras J, Feillet F, et al: International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria. Mol Genet Metab. 127:1–11. 2019.PubMed/NCBI View Article : Google Scholar
29	Muntau AC, Du Moulin M and Feillet F: Diagnostic and therapeutic recommendations for the treatment of hyperphenylalaninemia in patients 0-4 years of age. Orphanet J Rare Dis. 13(173)2018.PubMed/NCBI View Article : Google Scholar